ArticleTurkish journal of medical sciences2025
Benzyl alcohol improves Ang II-induced vascular and renal injury.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: The etiology of hypertension in pediatric populations is complex and multifactorial, with metabolic abnormalities playing a fundamental role in the pathogenesis of the condition. This study investigates the therapeutic effects of Benzyl alcohol (BA), identified through metabolomics analysis of pediatric hypertension serum, on Angiotensin II (Ang II)-induced vascular and renal injury in murine models. Materials and methods: Male C57BL/6 mice were used to establish a vascular remodeling model by continuous 4-week Ang II infusion using a subcutaneous osmotic pump. Bioinformatics was used to identify target metabolites. The tail artery, common carotid artery diastolic, and systolic pressures in mice were determined with a blood pressure monitor. Vascular structure changes were assessed with HE and Masson staining, while kidney pathology was examined using HE. Serum urea nitrogen, creatinine, and cystatin C levels were measured with ELISA kit. Results: Metabolomics analysis identified metabolite BA as a potential target for hypertension management. Compared to the Ang II group, BA reduced systolic blood pressure by 11.58% and diastolic blood pressure by 14.62% in the fourth week. After sodium nitroprusside treatment, the Ang II group showed reduced vasodilation reactivity versus the control. BA significantly restored this reactivity, unlike acetylcholine. Furthermore, BA was observed to attenuate Ang II-induced vascular mediator thickening, the mediator-to-lumen ratio, and collagen deposition. Ang II administration resulted in renal structural damage and increased concentrations of urea nitrogen, creatinine, and serum cystatin C, which was reversed by BA treatment. Conclusion: BA exhibits potential in enhancing the vasodilatory response, vascular remodeling, and renal injury associated with Ang II.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.